Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



GEN News Highlights

Back to Item »

Hospira Pays ChemGenex Roughly $16.25M Up Front for CML Therapy

Omacetaxine has been accepted for review in the U.S. and EU, and firms will evaluate the drug in other blood cancers.

Forward this item to a colleague:
Your name
Your email
(Separate multiple addresses by commas)
 
Colleague's email
(Separate multiple addresses by commas)
 
Personal Message
(optional)
 
 
 

GEN Poll

More » Poll Results » Archive »

GEN’s Hall of Shame

Will you be voting for any of the candidates on GEN’s Hall of Shame list in the next election?

Suggest a Poll